Palbociclib and Letrozole in Advanced Breast Cancer
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than with letrozole alone in the initial treatment of postmenopausal women with estrogen-receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We performed a phase 3 study that was designed to confirm and expand the efficacy and safety data for palbociclib plus letrozole for this indication. METHODS: In this double-blind study, we randomly assigned, in a 2:1 ratio, 666 postmenopausal women with ER-positive, HER2-negative breast cancer, who had not had prior treatment for advanced disease, to receive palbociclib plus letrozole or placebo plus letrozole. The primary end point was progression-free survival, as assessed by the investigators; secondary end points were overall survival, objective response, clinical benefit response, patient-reported outcomes, pharmacokinetic effects, and safety. RESULTS: The median progression-free survival was 24.8 months (95% confidence interval [CI], 22.1 to not estimable) in the palbociclib-letrozole group, as compared with 14.5 months (95% CI, 12.9 to 17.1) in the placebo-letrozole group (hazard ratio for disease progression or death, 0.58; 95% CI, 0.46 to 0.72; P<0.001). The most common grade 3 or 4 adverse events were neutropenia (occurring in 66.4% of the patients in the palbociclib-letrozole group vs. 1.4% in the placebo-letrozole group), leukopenia (24.8% vs. 0%), anemia (5.4% vs. 1.8%), and fatigue (1.8% vs. 0.5%). Febrile neutropenia was reported in 1.8% of patients in the palbociclib-letrozole group and in none of the patients in the placebo-letrozole group. Permanent discontinuation of any study treatment as a result of adverse events occurred in 43 patients (9.7%) in the palbociclib-letrozole group and in 13 patients (5.9%) in the placebo-letrozole group. CONCLUSIONS: Among patients with previously untreated ER-positive, HER2-negative advanced breast cancer, palbociclib combined with letrozole resulted in significantly longer progression-free survival than that with letrozole alone, although the rates of myelotoxic effects were higher with palbociclib-letrozole. (Funded by Pfizer; PALOMA-2 ClinicalTrials.gov number, NCT01740427 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“substantial PFS benefit and good toxicity profile.36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“These agents can be combined with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, in first or second line, in cases of primary or secondary resistance, in postmenopausal and premenopausal women (the latter with ovarian function suppression/ablation), and in men (preferably with a luteinising hormone-releasing hormone agonist).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“Although palbociclib was the first CDK4/6 inhibitor to demonstrate clinical efficacy (Finn et al., 2016), there are two others that soon followed.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Finn et al., 2016
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Self-citationCristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Self-citationFry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Y. Maximov, P., M. Lee, T., & Craig Jordan, V. (2013) · Current Clinical Pharmacology · doi:10.2174/1574884711308020006 · Cited by 376
Beaver, J. A., Amiri-Kordestani, L., Charlab, R., Chen, W., Palmby, T., Tilley, A., Zirkelbach, J. F., Yu, J., Liu, Q., Zhao, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1185 · Cited by 373
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Finn, R. S., Aleshin, A., & Slamon, D. J. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0661-5 · Cited by 368
Self-citationMartín, M., Loibl, S., von Minckwitz, G., Morales, S., Martinez, N., Guerrero, A., Anton, A., Aktas, B., Schoenegg, W., Muñoz, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.2388 · Cited by 131
Dickler, M. N., Barry, W. T., Cirrincione, C., Ellis, M. J., Moynahan, M. E., Innocenti, F., Hurria, A., Rugo, H. S., Lake, D. E., Hahn, O. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1595 · Cited by 128
Self-citation
Cited by
Items 901–1,000 of 1,002
Fuentes‐Antrás, J., de Luna, A., de Sá, A. L., Ocaña, A., García-Sáenz, J. Á., & Moreno, F. (2020) · The Breast · doi:10.1016/j.breast.2020.10.007 · Cited by 23
Rubovszky, G., Kocsis, J., Boér, K., Chilingirova, N. P., Dank, M., Kahán, Z., Kaidarova, D., Kövér, E., Vertáková-Krakovská, B., Máhr, K., et al. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610383 · Cited by 24
“Recommendations for Endocrine Therapies—In Postmenopause Patients With HR+ mBC As first-choice treatment for metastatic disease, combination of CDK4/6 inhibitors with NSAI significantly improvedmedian PFS (24–25 months) in all clinical trials [PALOMA-2 (77), MONALEESA-2 (78, 79), MONARCH-3 (80)] with acceptable side-e…”
BackgroundThe Evolving Role of Companion Diagnostics for Breast Cancer in an Era of Next-Generation Omics
Rosenbaum, J. N., & Weisman, P. S. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.04.021 · Cited by 26
“In these situations, therapy directed at inhibiting CDK4 and/or CDK6 (palbociclib; Novartis) may provide particular benefit.(65,66) As with BRCA1/BRCA2 testing, designing a companion diagnostic to capture all of the potential targets that might be responsive to anti-CDK4/CDK6 therapy poses challenges, and like MDM2 in…”
BackgroundAchieving Improved Survival Outcomes in Advanced Breast Cancer
Rugo, H. S. (2019) · New England Journal of Medicine · doi:10.1056/nejme1906236 · Cited by 23
Self-citationAdvanced Cancer as a Chronic Disease: Introduction
Pituskin, E., Joy, A. A., & Fairchild, A. M. (2021) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2021.151176 · Cited by 22
Yang, Y., Liao, J., Pan, Z., Meng, J., Zhang, L., Shi, W., Wang, X., Zhang, X., Zhou, Z., Luo, J., et al. (2024) · Advanced Science · doi:10.1002/advs.202413103 · Cited by 24
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer
Klocker, E. V., Egle, D., Bartsch, R., Rinnerthaler, G., & Gnant, M. (2025) · Drugs · doi:10.1007/s40265-024-02144-y · Cited by 25
Synergistic targeting strategies for prostate cancer
Li, X., Han, Z., & Ai, J. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01042-6 · Cited by 27
Updates on managing advanced breast cancer with palbociclib combination therapy
McShane, T. M., Wolfe, T. A., & Ryan, J. C. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918793849 · Cited by 21
Saux, O. L., Lardy-Cléaud, A., Frank, S., Debled, M., Cottu, P. H., Pistilli, B., Vanlemmens, L., Leheurteur, M., Lévy, C., Laborde, L., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.06.014 · Cited by 21
Schütz, F., Fasching, P. A., Welslau, M., Hartkopf, A. D., Wöckel, A., Lux, M. P., Janni, W., Ettl, J., Lüftner, D., Belleville, E., et al. (2019) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1001-9925 · Cited by 21
Hosoya, T., Saito, T., Baba, H., Tanaka, N., Noda, S., Komiya, Y., Tagawa, Y., Yamamoto, A., Mizoguchi, F., Kawahata, K., et al. (2021) · Rheumatology · doi:10.1093/rheumatology/keab874 · Cited by 21
Bolzacchini, E., Pomero, F., Fazio, M., Civitelli, C., Fabro, G., Pellegrino, D., Giordano, M., & Squizzato, A. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.11.009 · Cited by 21
A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis
Krishnamurthy, J., Luo, J. R., Suresh, R., Ademuyiwa, F. O., Rigden, C. E., Rearden, T. P., Clifton, K., Weilbaecher, K. N., Frith, A. E., Roshal, A., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00399-w · Cited by 23
Racial disparities in breast cancer preclinical and clinical models
Clarke, S., Chin, S. N., Dodds, L. V., George, S. H. L., & Badal, S. A. M. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01551-x · Cited by 23
Xu, H., Wang, Y., Han, Y., Wu, Y., Wang, J., & Xu, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.956464 · Cited by 24
“06 II Pictilisib + Fulvestrant (41) Placebo + Fulvestrant (20) 0(12)/1(27)/ 2(20)/≥3(41) 0(10)/1(35)/ 2(25)/≥3(30) 17 25 51 50”
InfluentialEndocrine therapy resistance: what we know and future directions
Musheyev, D., & Alayev, A. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00096 · Cited by 21
“Palbociclib, ribociclib, and abemaciclib are currently FDA-approved CDK4/6 inhibitors and are used in combination with endocrine therapies for the treatment of ER-positive/ HER2-negative breast cancer [107, 108].”
BackgroundDouganiotis, G., Kesisis, G., Lalla, E., Korantzis, I., Boukovinas, I., & Papazisis, K. T. (2022) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10146 · Cited by 24
Zhou, J., Wu, X., Zhang, H., Wang, X., Yuan, Y., Zhang, S., Jiang, Z., & Wang, T. (2022) · The Breast · doi:10.1016/j.breast.2022.10.018 · Cited by 23
Mouabbi, J. A., Raghavendra, A. S., Bassett, R. L., Hassan, A. A., Tripathy, D., & Layman, R. M. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00499-7 · Cited by 21
Watson, N. W., Shatzel, J. J., & Al-Samkari, H. T. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2022.12.001 · Cited by 22
Queiroz, M. M., Sacardo, K. P., Ribeiro, M. F., Gadotti, L. L., Saddi, R., Oliveira, L. J. D. C., Linck, R. D. M., Cruz, M. R. D. S., Barroso‐Sousa, R., Sahade, M., et al. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100683 · Cited by 22
Pasqualoni, M., Orlandi, A., Palazzo, A., Garufi, G., Cannizzaro, M. C., Pontolillo, L., Pannunzio, S., Cutigni, C., Sollena, P., Federico, F., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1067264 · Cited by 21
A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer
Meng, D., Zhao, X., Yang, Y. C., Navickas, A., Helland, C., Goodarzi, H., Singh, M., & Bandyopadhyay, S. (2023) · Oncogene · doi:10.1038/s41388-023-02737-z · Cited by 21
“fulvestrant [25] and 24 months with the CDK4/6 inhibitor palbociclib [26].”
BackgroundCurigliano, G., Dent, R. A., Llombart‐Cussac, A., Pegram, M. D., Pusztai, L., Turner, N. C., & Viale, G. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00560-z · Cited by 25
Masuda, H., Tanabe, Y., Sakai, H., Matsumoto, K., Shimomura, A., Doi, M., Miyoshi, Y., Takahashi, M., Sagara, Y., Tokunaga, S., et al. (2023) · The Breast · doi:10.1016/j.breast.2023.07.003 · Cited by 23
New agents for endocrine resistance in breast cancer
Maurer, C., Martel, S., Zardavas, D., & Ignatiadis, M. (2017) · The Breast · doi:10.1016/j.breast.2017.04.007 · Cited by 22
Martel, S., Bruzzone, M., Ceppi, M., Maurer, C., Ponde, N. F., Ferreira, A. R., Viglietti, G., Mastro, L. D., Prady, C. C. M., de Azambuja, E., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.09.009 · Cited by 23
Pascual, T., Martín, M., Fernández-Martínez, A., Paré, L., Alba, E., Rodríguez-Lescure, Á., Perrone, G., Cortés, J., Morales, S. M., Lluch, A. M., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00303 · Cited by 21
“Recently, gene expression data from the PALOMA-2 clinical trial have been presented (21, 22).”
BackgroundWilson, B. E., Mok, K., Kiely, B. E., Nguyen, R. H., & Moylan, E. J. (2019) · Internal Medicine Journal · doi:10.1111/imj.14629 · Cited by 22
Pharmacological cancer treatment and venous thromboembolism risk
Martín, A. J. M., Ramírez, S. P., Morán, L. O., Zamorano, M. R., Viñuela-Benéitez, M. C., Aparicio, I., Escobar, I. G., & Soria, J. M. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa004 · Cited by 23
What’s the Price? Toxicities of Targeted Therapies in Breast Cancer Care
Anders, C. K., LeBoeuf, N. R., Bashoura, L., Faiz, S. A., Shariff, A. I., & Thomas, A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279465 · Cited by 21
Louveau, B., Resche‐Rigon, M., Lesimple, T., Meda, L. D., Pracht, M., Baroudjian, B., Delyon, J., Amini‐Adlé, M., Dutriaux, C., de Moura, C. R., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4050 · Cited by 23
“As CDK4/6is such as palbociclib, abemaciclib, and ribociclib are already available in clinical practice and have been shown to significantly improve survival in HRþ/HER2 advancedmetastatic breast cancer (20, 21), these data support the clinical evaluation of CDK4/6is to overcome resistance toMAPKis inmelanoma.”
ResultA Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer
Mo, H., Jazieh, K., Brinzevich, D., & Abraham, J. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.05.014 · Cited by 25
Olazagasti, C., Lee, C., Liu, A., Stefanov, D. G., & Cheng, K. C. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211050106 · Cited by 21
“In the Paloma trial, only 36% of the subjects on the experimental arm (palbociclib) had one or more dose reductions with 22% and 14% of subjects having one and two reductions, respectively.(6) All dose reductions from these clinical trials were due to adverse events.”
BackgroundMuttiah, C., Whittle, J. R., Oakman, C. A., & Lindeman, G. J. (2022) · Future Oncology · doi:10.2217/fon-2021-1450 · Cited by 23
Mycock, K., Hanson, K. A., Taylor‐Stokes, G., Milligan, G., Atkinson, C., Mitra, D., Preciado, S. M., & Law, E. H. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.11.004 · Cited by 21
Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers
Wilson, T. R., Udyavar, A. R., Chang, C., Spoerke, J. M., Aimi, J., Savage, H. M., Daemen, A., O’Shaughnessy, J., Bourgon, R., & Lackner, M. R. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0619 · Cited by 21
“These results are timely given the beneficial effects of CDK4/6 inhibitors in HR+ metastatic breast cancer (35), with the results from adjuvant studies eagerly anticipated.”
ResultPalbociclib enhances activin‐ SMAD ‐induced cytostasis in estrogen receptor‐positive breast cancer
Harada, M., Morikawa, M., Ozawa, T., Kobayashi, M., Tamura, Y., Takahashi, K., Tanabe, M., Tada, K., Seto, Y., Miyazono, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13841 · Cited by 22
Battisti, N. M. L., Kingston, B., King, J. P., Denton, A. S., Waters, S. H., Sita-Lumsden, A. R., Rehman, F. L., Stavraka, C., Kristeleit, H., Sawyer, E. J., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05134-x · Cited by 22
CDK Inhibitors and FDA: Approved and Orphan
Cicenas, J., & Simkus, J. (2024) · Cancers · doi:10.3390/cancers16081555 · Cited by 24
“Its approval was based on a randomized, multicenter, open-label phase I/II trial, PALOMA-1 [16], which was confirmed by PALOMA-2 [17] and PALOMA-4 [18] phase III trials.”
MethodHarbeck, N., Brufsky, A., Rose, C. G., Korytowsky, B., Chen, C., Tantakoun, K., Jazexhi, E., Nguyen, D. H. V., Bartlett, M., Samjoo, I. A., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1530391 · Cited by 20
Self-citationSaha, T., & Lukong, K. E. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1513225 · Cited by 23
“…— have demonstrated signi fi cantly improved progression-free survival (PFS) and overall survival (OS) compared to fulvestrant or AI monotherapy (39 – 41) Additionally, targeting the PI3K/AKT/mTOR signaling cascade with mTOR inhibitors, such as everolimus, represents a signi fi cant advancement…”
Ananthula, A., Lockwood, M. B., Savage, J., Malak, S. F., Chen, C., Makhoul, I., & Pennisi, A. (2020) · The Permanente Journal · doi:10.7812/tpp/19.084 · Cited by 20
Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
Andrikopoulou, Α., Fiste, O., Liontos, M., Dimopoulos, M. A., & Zagouri, F. (2021) · Cancers · doi:10.3390/cancers13030465 · Cited by 21
“45% of patients enrolled in the PALOMA-2 trial, while no fracture was reported in patients receiving ribociclib plus letrozole in MONALEESA-2 trial and only one patient presented with a fracture in the MONALEESA-7 trial [9,10,24,57,58].”
BackgroundLu, Y., Yeo, W., Yap, Y. S., Park, Y. H., Tamura, K., Li, H., & Cheng, R. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00838-x · Cited by 24
“74) in the PALOMA-2 study (Table 2) [59].”
Dowsett, M., Kilburn, L., Rimawi, M. F., Osborne, C. K., Pogue-Geile, K., Liu, Y., Jacobs, S. A., Finnigan, M., Puhalla, S., Dodson, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1628 · Cited by 21
“org Clin Cancer Res; 28(1) January 1, 2022 167”
BackgroundInfluentialStamuli, E., Corry, S., Ross, D., Konstantopoulou, T., Texeira, L., Avouac, B. P., Debiais, D., Yates, L. R., Behis, A., McLoughlin, A., et al. (2022) · Future Oncology · doi:10.2217/fon-2021-0635 · Cited by 23
Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer
Main, S. C., Cescon, D. W., & Bratman, S. V. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.37 · Cited by 24
Al‐Rashdan, A., Quirk, S., Roumeliotis, M. B., Abedin, T., Amaro, C. P., Barbera, L. C., Lupichuk, S., & Cao, J. Q. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.07.005 · Cited by 20
Wang, S., Bei, Y., Tian, Q., He, J., Wang, R., Wang, Q., Sun, L., Ke, J.-Q., Xie, C., & Shen, P. (2022) · Cell Proliferation · doi:10.1111/cpr.13337 · Cited by 21
“However, Pfizer funded the PALOMA-2 clinical trial and randomly assigned 666 women with ER(+)/HER2( ) advanced BC in 17 countries from February 2013 to July 2014.(13) Among these patients, more than 35% experienced disease progression and cancer recurrence during CDK4/6 inhibitor treatment for 2 years.”
BackgroundMethodChen, W., Ji, M., Cheng, H., Zheng, M., Xia, F., Min, W., Yang, H., Wang, X., Wang, L., Cao, L., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00947 · Cited by 21
Clark, A. S., Hong, F., Finn, R. S., DeMichele, A. M., Mitchell, E. P., Zwiebel, J. A., Arnaldez, F. I., Gray, R. J., Wang, V., McShane, L. M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2150 · Cited by 22
“Results were confirmed in a randomized doubleblinded placebo-controlled phase III trial (8).”
BackgroundResultSelf-citationRugo, H. S., Liu, X., Li, B. C., McRoy, L., Chen, C., Layman, R. M., & Brufsky, A. (2023) · International Journal of Cancer · doi:10.1002/ijc.34748 · Cited by 21
Self-citationShao, H., Zhao, M., Guan, A., Shao, T., Zhou, D., Yu, G., & Tang, W. (2024) · BMC Medicine · doi:10.1186/s12916-023-03238-2 · Cited by 21
Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review
Brain, E. G. C., Chen, C., Simon, S., Pasupuleti, V., Pfitzer, K. V., & Gelmon, K. A. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01046-z · Cited by 22
“In PALOMA-2 and PALOMA-3, the median age of patients who received palbociclib was 62 years and 57 years, respectively, while the largest RWE study population included in this review had a median age of 67 years [23, 52, 69].”
BackgroundSelf-citationGarrido-Castro, A. C., Graham, N., Ali, L. R., Herold, C. I., Desrosiers, J., Do, K., Parsons, H. A., Li, T., Goel, S., DiLullo, M. K., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010430 · Cited by 21
“48”
Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies
Angelousi, A. G., Dimitriadis, G. K., Zografos, G., Nölting, S., Kaltsas, G., & Grossman, A. B. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0542 · Cited by 21
Pre-operative Endocrine Therapy
Arthur, L. M., Turnbull, A., Khan, L. R., & Dixon, J. M. (2017) · Current Breast Cancer Reports · doi:10.1007/s12609-017-0255-6 · Cited by 20
Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series
Giannone, G., Milani, A., Ghisoni, E., Genta, S., Mittica, G., Montemurro, F., & Valabrega, G. (2018) · The Breast · doi:10.1016/j.breast.2018.01.006 · Cited by 20
Petrossian, K., Kanaya, N., Lo, C., Hsu, P.-Y., Nguyen, D. M., Yang, L., Yang, L., Warden, C., Wu, X., Pillai, R. K., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25552 · Cited by 23
“Progression free survival (PFS) of palbociclib, in combination with endocrine therapy, in ER+/HER2breast cancer patients has been reported in PALOMA-1 [23], PALOMA-2 [24] and PALOMA-3 [25, 26].”
BackgroundBrufsky, A., Mitra, D., Davis, K. L., Nagar, S. P., McRoy, L., Cotter, M. J., & Stearns, V. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.04.005 · Cited by 20
Hachem, G. E., Gombos, A., & Awada, A. H. (2019) · F1000Research · doi:10.12688/f1000research.17542.1 · Cited by 21
Morris-Hanon, O., Marazita, M. C., Romorini, L., Isaja, L., Espinosa, D. D. F., Sevlever, G. E., Scassa, M. É., & Videla-Richardson, G. A. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1633-z · Cited by 23
Consenso Mexicano sobre diagnóstico y tratamiento del cáncer mamario. Octava revisión. Colima 2019
Cárdenas-Sánchez, J., Erazo-Valle-Solís, A. A., Arce-Salinas, C., Bargalló‐Rocha, E., Piña, V. B., Cervantes-Sánchez, M. G., Flores-Balcázar, C. H., Lluch-Hernández, A., Maffuz‐Aziz, A., Pérez-Sánchez, V. M., et al. (2019) · Gaceta Mexicana de Oncología · doi:10.24875/j.gamo.m19000180 · Cited by 33
Odan, N., Kikawa, Y., Matsumoto, H., Minohata, J., Suwa, H., Hashimoto, T., Okuno, T., Miyashita, M., Saito, M., Yamagami, K., et al. (2020) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223420983843 · Cited by 22
“Treatment lines of palbociclib, median (range) 4 (1-13)”
BackgroundChawla, S., Hill, A., Fearfield, L. A., Johnston, S. R. D., Parton, M., & Heelan, K. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06169-9 · Cited by 21
Gión, M., Pérez-García, J. M., Llombart‐Cussac, A., Sampayo-Cordero, M., Cortés, J., & Malfettone, A. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211059587 · Cited by 22
Habler, K., Kalla, A.-S., Rychlik, M., Vogeser, M., & Teupser, D. (2022) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2022.115211 · Cited by 22
Yam, C., Murthy, R. K., Rauch, G. M., Murray, J. L., Walters, R. S., Valero, V., Brewster, A. M., Bast, R. C., Booser, D. J., Giordano, S. H., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0672-z · Cited by 20
Self-citationGiachetti, P. P. M. B., Morganti, S., Gandini, S., Giudici, F., Marra, A., Nicolò, E., Zattarin, E., Corti, C., Boldrini, L., Verrazzo, A., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.61067 · Cited by 22
Wu, X., & Dai, W. (2025) · Cancers · doi:10.3390/cancers17213408 · Cited by 22
Huber, M., Bauer, L. S., Gruber, F. K., & Müller, E. W. (2025) · Archive of International Journal of Cancer and Allied Science · doi:10.51847/sjnxeirzxn · Cited by 19
Wortelboer, N., van Ommen‐Nijhof, A., Konings, I. R. H. M., van der Noort, V., van den Pol, E., Páez, C. G., Bakker, S. D., Hovenga, S., Imholz, A. L. T., Kamm, Y. J. L., et al. (2026) · JAMA Oncology · doi:10.1001/jamaoncol.2025.6585 · Cited by 22
Matikas, A., Foukakis, T., & Bergh, J. C. S. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.04.002 · Cited by 19
Zhou, Z., Liu, Y., Ren, Q., Yu, D.-H., & Lü, H. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.130261 · Cited by 19
T Cell-Intrinsic CDK6 Is Dispensable for Anti-Viral and Anti-Tumor Responses In Vivo
Klein, K., Witalisz‐Siepracka, A., Gotthardt, D., Agerer, B., Sternberg, F., Grausenburger, R., Knab, V. M., Bergthaler, A., & Sexl, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.650977 · Cited by 19
Senolysis Reduces Senescence in Veins and Cancer Cell Migration
Estepa‐Fernández, A., Alfonso, M., Morellá‐Aucejo, Á., García‐Fernández, A., Lérida‐Viso, A., Lozano‐Torres, B., Galiana, I., Soriano‐Teruel, P. M., Sancenón, F., Orzáez, M., et al. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100149 · Cited by 20
Alsaleh, K. A., Zahwahry, H. A., Bounedjar, A., Oukkal, M., Saadeddine, A., Mahfouf, H., Bouzid, K., Bensalem, A., Filali, T., Abdel‐Razeq, H., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04588-3 · Cited by 19
“Fulvestrant, a selective estrogen receptor degrader (SERD), remains one of the most potent hormone therapies in metastatic BC (Suman et al. 2015; Finn et al. 2016; Turner et al. 2018a).”
InfluentialAdvances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer
Ziyeh, S., Wong, L., & Basho, R. K. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01393-6 · Cited by 20
“MONALEESA-2 [22, 72] Postmenopausal women (N = 668) Ribociclib + letrozole 25.”
Clinical trial designs for evaluating and exploiting cancer evolution
Garces, A. I., Porta, N., Graham, T. A., & Banerji, U. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102583 · Cited by 19
Hopcroft, L., Wigmore, E. M., Williamson, S. C., R�os, S., Eberlein, C., Moss, J. I., Urosevic, J., Carnevalli, L. S., Talbot, S., Bradshaw, L., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00571-w · Cited by 23
“The addition of CDK4/6 inhibitors to endocrine therapy increases therapeutic bene fi t in ER + tumours and is now a commonly used treatment 10 – 12 .”
MethodSelf-citationTang, H., Yeo, D., DeSouza, K., Ahmad, O., Shafiq, T., Ofor, O., Anand, A., Karim, S., Khan, S. N., & Madhusudan, S. (2023) · Cancers · doi:10.3390/cancers15215164 · Cited by 21
“Patients underwent regular clinical, biochemical and radiological surveillance with three monthly CT cross-sectional imaging as per protocol [17–21].”
BackgroundMethodInfluentialMehraji, S., Saadatmand, M., & Eskandari, M. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.129685 · Cited by 19
CDK4/6 inhibitors: The Devil is in the Detail
Magge, T., Rajendran, S., Brufsky, A., & Foldi, J. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01540-7 · Cited by 20
“…treatments for patients with advanced hormone receptor (HR)- positive, human epidermal growth factor receptor 2 (HER2)- negative breast cancers, based on improved progression free survival (PFS) and in some cases, overall survival (OS) in the phase III PALOMA, MONALEESA and MONARCH studies [1–8].”
Attwa, M. W., Abdelhameed, A. S., & Kadi, A. A. (2024) · Journal of Separation Science · doi:10.1002/jssc.202400346 · Cited by 19
Advances in Personalized Oncology
Mechahougui, H., Gutmans, J., Colarusso, G., Gouasmi, R., & Friedlaender, A. (2024) · Cancers · doi:10.3390/cancers16162862 · Cited by 21
“Palbociclib, in combination with letrozole, has significantly extended PFS by 24.8 months, as demonstrated in the PALOMA-2 trial [58].”
BackgroundInfluentialDarden, C., Mitra, D., McSorley, D., Davis, K. H., Band, J., & Iyer, S. S. (2018) · Future Oncology · doi:10.2217/fon-2018-0531 · Cited by 19
He, M., Li, J., Zuo, W., Ji, L., Jiang, Y., Hu, X., Wang, Z., & Shao, Z.-M. (2019) · Cancer Medicine · doi:10.1002/cam4.2453 · Cited by 20
Farhat, F. S., Tarabaih, M., Kanj, A., Aoun, M., Kattan, J. G., Assi, T., & Awada, A. H. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000845 · Cited by 20
Russell-Goldman, E. E., & Nazarian, R. M. (2020) · Journal of Cutaneous Pathology · doi:10.1111/cup.13673 · Cited by 19
“Clinical trials found that using palbociclib in combination with letrozole in patients with advanced estrogen receptor (ER) positive, HER2-negative breast cancer resulted in significantly longer progression-free survival than in those patients treated with letrozole alone.(6) Palbociclib is now used in this patient po…”
Severe rhabdomyolysis induced by possible drug–drug interaction between Ribociclib and Simvastatin
Streicher, C., Daulange, A., Madranges, N., & Vayre, L. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220945365 · Cited by 19
Kessler, L. E., Wiklander, O. P. B., Hamberg, E., Bergh, J. C. S., Foukakis, T., & Matikas, A. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1804613 · Cited by 20
Abemaciclib, a CDK4 and CDK6 Inhibitor for the Treatment of Metastatic Breast Cancer
Martín, M., García-Sáenz, J. Á., Manso, L., Llombart‐Cussac, A., Cassinello, A., Atienza, M., Ringeisen, F. P., & Ciruelos, E. (2020) · Future Oncology · doi:10.2217/fon-2020-0604 · Cited by 20
Porte, B., Carton, M., Lerebours, F., Brain, E. G. C., Loirat, D., Haroun, L., Bellesœur, A., Hamba, S. B., Kirova, Y., & Cottu, P. H. (2020) · The Breast · doi:10.1016/j.breast.2020.11.008 · Cited by 19
“In the PALOMA-2 trial, 666 postmenopausal women were treated by palbociclib-letrozole or with placebo-letrozole in mostly endocrine sensitive patients in the first line setting [11].”
MethodKawakami, M., Mustachio, L. M., Chen, Y., Chen, Z., Liu, X., Wei, C.-H., Roszik, J., Kittai, A. S., Danilov, A. V., Zhang, X., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0987 · Cited by 20
“Although pharmacologic inhibition of specific CDK family members such as CDK4/6 is FDA approved for a subset of breast cancers (21, 22), clinical validation of CDK2 inhibitors for cancer therapy is not yet established.”
Li, Y., Li, L., Du, Q., Li, Y., Yang, H., & Li, Q. (2021) · Cancer Investigation · doi:10.1080/07357907.2021.1910705 · Cited by 19
Ribociclib induced acute kidney injury: A case report
Gültürk, İ., Yılmaz, M., Özmen, A., Tacar, S. Y., Erdal, G. Ş., & Tural, D. G. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211007202 · Cited by 20
Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer
Fang, H., Cavaliere, A., Li, Z., Huang, Y. H., & Marquez-Nostra, B. V. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.627693 · Cited by 20
“Palbociclib, a CDK4/6 inhibitor (CDKi), is in phase 3 clinical trials for the treatment of ERpositive advanced breast cancer (Finn et al., 2016).”
BackgroundXu, J. J., Chalk, A. M., Nikolić, I., Simpson, K. J., Smeets, M. F. M. A., & Walkley, C. R. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004571 · Cited by 20
Metadata
- Authors
- Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., Gauthier, E., Lu, D. R., Randolph, S., Diéras, V., & Slamon, D. J.
- Affiliations
- Universidad Complutense de Madrid (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-17
- Volume
- 375
- Issue
- 20
- Pages
- 1925-1936
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2552099557
- Cited by
- 3,007
- References
- 12
- Citations by year
- 2026: 278 · 2025: 346 · 2024: 349 · 2023: 343 · 2022: 310 · 2021: 363 · 2020: 299 · 2019: 260 · 2018: 284 · 2017: 157 · 2016: 9
- FWCI
- 210.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Health Research Board (ICORG-2016-1)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- palbociclib, letrozole, advanced breast cancer, estrogen receptor-positive breast cancer, HER2-negative breast cancer, CDK4/6 inhibitors, progression-free survival, postmenopausal women, neutropenia, febrile neutropenia, overall survival, first-line therapy, drug safety and tolerability, patient-reported outcomes, pharmacokinetics, objective response rate
- MeSH terms
- Letrozole, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Humans, Middle Aged, Neutropenia, Nitriles, Piperazines, Pyridines, Receptors, Estrogen, Triazoles, Postmenopause, Disease-Free Survival, Cyclin-Dependent Kinases, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.